Detalhe da pesquisa
1.
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 380(8): 741-751, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30786188
2.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Cancer
; 123(19): 3843-3854, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558150
3.
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).
Ann Rheum Dis
; 80(7): 954-955, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619162
4.
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.
Haematologica
; 101(11): 1327-1332, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27515248
5.
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Br J Haematol
; 169(5): 701-10, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25847298
6.
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Pediatr Blood Cancer
; 62(7): 1171-5, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25732247
7.
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.
Rheumatology (Oxford)
; 53(3): 502-11, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24273022
8.
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Haematologica
; 99(11): 1738-45, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25150258
9.
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Br J Haematol
; 163(4): 478-86, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24112026
10.
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
Br J Haematol
; 162(5): 693-701, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23829485
11.
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
Rheumatology (Oxford)
; 52(7): 1313-22, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23542611
12.
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
Eur J Haematol
; 91(6): 552-6, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23927500
13.
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Cancer
; 118(22): 5497-506, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22569804
14.
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Haematologica
; 102(5): e184-e186, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28154086
15.
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
Haematologica
; 96(4): 567-73, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21173095
16.
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Haematologica
; 100(4): e128-31, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25552705
17.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Haematologica
; 93(3): 390-7, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18268287
18.
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Arthritis Rheumatol
; 70(5): 763-773, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381843
19.
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
J Clin Oncol
; 35(29): 3338-3346, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817371
20.
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
J Clin Oncol
; 35(24): 2790-2797, 2017 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548889